{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:02:23Z","timestamp":1789909343546,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2018\/02\/X\/NZ7\/00727"],"award-info":[{"award-number":["2018\/02\/X\/NZ7\/00727"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/32\/C\/NZ7\/00156"],"award-info":[{"award-number":["2019\/32\/C\/NZ7\/00156"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite new therapies, the estimated 229\u2009875 women living with ovarian cancer have a 5\u2010year survival rate of 47.6%. This cavity\u2010localized cancer lends itself to local administration of modalities, such as the oncolytic adenovirus (Ad) Ad5\/3\u2010D24\u2010granulocyte\u2010macrophage colony\u2010stimulating factor virus (ONCOS\u2010102). Its repeated administration to a patient with chemotherapy\u2010refractory ovarian cancer induced CD8+ antitumor immune responses with the overall survival reaching 40 months. Here we probe the dominant receptor used by ONCOS\u2010102 in four established epithelial ovarian cancer cell lines. Ad3 can use the desmoglein\u20102 (DSG2) and CD46 receptors on susceptible cells. DSG2 was nearly absent in A2780 cells but was expressed in more than 90% of OAW42, OVCAR3, and OV\u201090 cells. After 96\u2009hours, ONCOS\u2010102 treatment showed significant oncolytic activity (\u226750%) in OAW42, OVCAR3, and OV\u201090 cells, but minimal activity in A2780 cells, suggesting DSG2 as the dominant receptor for ONCOS\u2010102. Furthermore, retrospective analyses of phase I clinical trial of ONCOS\u2010102 treatment of 12 patients with varied tumors indicated a correlation between viral genomes in blood and DSG2 RNA expression. These data support the role of DSG2 expression on cancer cells in virus infectivity and the continued development of ONCOS\u2010102 for ovarian cancer treatment.<\/jats:p>","DOI":"10.1002\/jmv.25677","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T08:05:35Z","timestamp":1579161935000},"page":"1309-1315","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein\u20102 cell entry receptor"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-6361","authenticated-orcid":false,"given":"Lukasz","family":"Kuryk","sequence":"first","affiliation":[{"name":"Clinical Science Targovax Oy  Helsinki Finland"},{"name":"Department of Virology National Institute of Public Health \u2013 National Institute of Hygiene  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Sophie W.","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Clinical Science Targovax ASA  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Cancer Facts and Figures 2019","author":"American Cancer Society","year":"2019"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.02.052"},{"key":"e_1_2_9_4_1","unstructured":"Surveillance Epidemiology and End Results Program.Cancer Stat Facts: Ovarian Cancer. National Cancer Institute.2019.https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed January 22 2020."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0014-6"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060201"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.2"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0559"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.12.022"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.05.015"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1319028"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.34824"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030621"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/v10100558"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0038-x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1017702"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.22"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25229"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.161"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83142-0"},{"issue":"6","key":"e_1_2_9_21_1","first-page":"4943","article-title":"CD46 expression is indicative of shorter revival\u2010free survival for ovarian cancer patients","volume":"26","author":"Surowiak P","year":"2006","journal-title":"Anticancer Res"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-011-9401-0"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2270"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201000811"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29536"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2546"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25501"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1532763"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0121-5"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182715"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30228"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41941-4"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12290"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-17-0289"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06181-11"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan2507"},{"key":"e_1_2_9_37_1","unstructured":"Human Protein Atlas.Pathology Atlas: Ovarian cancer DSG2. Human Protein Atlas.2019.https:\/\/www.proteinatlas.org\/ENSG00000046604\u2010DSG2\/pathology\/tissue\/ovarian+cancer#Quantity. Accessed September 3 2019."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0645"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00514-11"},{"issue":"17","key":"e_1_2_9_40_1","first-page":"5481","article-title":"Desmoglein\u20102 overexpression predicts poor prognosis in hepatocellular carcinoma patients","volume":"22","author":"Han CP","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10216"},{"issue":"12","key":"e_1_2_9_42_1","first-page":"4908","article-title":"Efficacy with a replication\u2010selective adenovirus plus cisplatin\u2010based chemotherapy: dependence on sequencing but not p53 functional status or route of administration","volume":"6","author":"Heise C","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.147"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.25677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T11:55:26Z","timestamp":1693914926000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/jmv.25677"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25677","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"2019-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}